Skip to main content

Change location

You are currently on the South Korea (English) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Careers
  • Media and News
  • Get in touch
    • South Korea (한국어)
  • Home
  • we are bracco
    We are Bracco

    Welcome to a World of contrasts

    • Our businesses
    • Purpose and values
    • Our history
    • 재단
    • Responsibility and Ethical conduct
  • Our Portfolio

    Proven offerings for a proven difference

    • X-ray/CT
      • Contrast agents

        • Iopamiro 300
        • Iopamiro 370
        • Iomeron 300
        • Iomeron 350
        • Iomeron 400
      • Medical devices

        • CT Exprès
        • Empower CTA +
    • MRI
      • Contrast agents

        • MultiHance Pre-filled Syringe
        • ProHance Injection
        • ProHance Pre-filled Syringe
      • Medical Devices

        • Empower MR
    • Ultrasound
      • Contrast agents

        • SonoVue
      • Software

        • VueBox
    • Digital solutions
    • Oncology
    • Cardiology
  • Woman looking into microscope
    Innovation

    A deep dive into our R&D progress

    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
  • knowledge
    Knowledge

    Current activities and future opportunities

    • E-learning
    • Partnerships in education
    • Event calendar
  • Ceriano Laghetto
    Sustainability

    Our game plan and goals for a better world

    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our Stories
Product
Empower MR World's first hydraulic-powered MR injector eliminates batteries and associated issues.
Bracco logo
Product
SonoVue SonoVue® is a second-generation ultrasound contrast agent, designed and optimized for pressure resistance. As a result of many years of research and development conducted within Bracco, SonoVue® is a second-generation ultrasound contrast agent designed and optimized with regard to the resistance to pressure.
Bracco logo
Product
VueBox From qualitative to quantitative analysis of linear data cross-platform compatibility, VueBox™ is a general-purpose software application for quantifying tissue perfusion using Dynamic Contrast-Enhanced Ultrasound (DCE-US).
Bracco logo
Article
The Bracco Fellowships are back 95 grants to celebrate Bracco’s 95th Anniversary
fellowship
Article
FDA approves Gadopiclenol injection for the U.S. market Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY™ (gadopiclenol) injection and VUEWAY™ (gadopiclenol) Pharmacy Bulk Package by Bracco.
Vueway Gadopiclenol
Page
Distributors list Distributors list
Bracco logo
Product
EmpowerCTA Efficiency and Control at your fingertips.
Bracco logo
Page
Data protection Data Protection
Bracco logo
Page
Cookie Policy Cookie Policy
Bracco logo
Page
Search Search
Bracco logo
  • Load More

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our Portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our Stories
  • Pharmacovigilance
  • Data Protection

Connect with us

Via Egidio Folli 50
20134 Milan, Italy
Phone + 39 02 2177.1

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182